Neurological damage in brain injury occurs due to secondary brain injury. Kencur extract has antioxidant potential with total phenolic and flavonoid content including luteolin apigenin and is expected to reduce MDA expression to prevent secondary injury. This study is an experimental laboratory. The treatment of all samples was carried out simultaneously using a post-test-only control group design. Based on the ANOVA test, the significance value of the Kencur extract treatment group was 0.000 (p<0.05) indicating that there was a difference in MDA expression in brain-injured rats without kencur extract with brain-injured rats and given kencur extract. In the 24-hour and 48-hour time groups, a significance value of 0.488 (p> 0.05) showed no significant difference in MDA expression. Then the Kencur extract treatment group with a time group of 0.117 (p> 0.05) showed no significant difference in MDA expression. There was a significant difference in the expression of MDA in brain-injured rats without kencur extract with brain-injured rats and given kencur extract. There were no significant differences in the MDA expression in the 24-hour and 48-hour time groups and the Kencur extract treatment group and the 24-hour and 48-hour time groups.